European Archives - Page 294 of 899 - European Medical Journal

EMJ Dermatology 10 [Supplement 2] 2022

Presentations from the Virtual 30th European Academy of Dermatology and Venereology (EADV) Congress 2021 discussed the potential of targeting the IL-23 pathway as a biologic treatment for psoriatic arthritis (PsA) and psoriasis (PsO).

EMJ Oncology 10 [Supplement 2] 2022 feature

3rd February 2022

Optimising Cholangiocarcinoma Diagnosis and Treatment Focusing on Precision Medicine

This article is based on interviews conducted with Lorenza Rimassa, Arndt Vogel, and Harpreet Wasan. They provided their expert opinion…

EMJ Dermatology 10 [Supplement 1] 2022

‘Diving Deep: Harnessing the Potential of the IL-23 Pathway’, a satellite symposium session presented at the 30th European Academy of Dermatology and Venerology (EADV) Virtual Congress, featuring Bruce E. Strober, Daniel Aletaha, and Jo L.W. Lambert…

3rd February 2022

With a Little Help From My Friends: Understanding the IL-23 Pathway and Managing Psoriasis and Psoriatic Arthritis

An infographic based on a satellite symposium from the 2021 ESDR Annual Meeting delves into the IL-23 pathway and the management of PsO…

Diversity: from ideas to action

The pharmaceutical industry is on a journey to create more diverse and inclusive working cultures. Read the article to find out more.

2nd February 2022

A new asset in contraception: E4 14.2 mg + DRSP 3 mg

In this podcast three leading experts from the field of gynecology and hemostasis discuss the brief history and development of combined oral contraceptives.

Risks to supply chain stability

In the wake of COVID-19, GOLD investigates the potential impact of unpredictable events on the industry’s complex distribution network to understand its resilience and vulnerability.

1st February 2022

Oesophageal Cancer: Current Treatment Landscapes and a Look to the Future

In this podcast, hosted by Julie Ann Lough, experts in oesophageal cancer come together to discuss current treatments…

EMJ Hematology 10 [Supplement 1] 2022

Multiple myeloma (MM) is an incurable disease and is the second most common haematologic malignancy in the world. Over the past decade…

31st January 2022

Updates on Isatuximab in Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

In the past decade, therapies that are more effective and less toxic have transformed the treatment landscape for patients with MM…